Facility expansion Asia-Pacific · 7d ago

HLB Pharmaceutical Starts $41.4 Million Tablet Plant in Hwaseong, South Korea

HLB Pharmaceutical begins building a 55 billion won tablet plant in Hwaseong, boosting capacity to 700 million tablets by 2029 to reach 1 trillion won sale

RD

Research Desk

· 3 min read

HLB Pharmaceutical Starts $41.4 Million Tablet Plant in Hwaseong, South Korea

HLB Pharmaceutical has begun construction of a new tablet manufacturing plant in the Hyangnam area of Hwaseong, Gyeonggi Province, backed by an investment of USD 41.4 million.

Targeting USD 749.19 million by 2036

The groundbreaking took place on Thursday and forms part of the drugmaker's plan to reach USD 749.19 million in annual sales by 2036 and rank among Korea's 10 largest pharmaceutical companies. Chairman Jin Yang-gon of HLB Group attended the ceremony and said the plant would concretely realize the group's corporate mission of "Human Life Better," describing it as "a production site that can be trusted by any standards with top-level quality and cutting-edge equipment."

Nearly triple current output

The Hyangnam facility is expected to produce about 700 million tablets annually, close to three times the roughly 250 million tablets a year currently made at the company's Namyangju plant. CEO Park Jae-hyung said the existing capacity had made it difficult to keep up with rising demand, forcing the company to lean heavily on external production.

"The new Hyangnam plant, which breaks ground today, is our answer to this task," Park said at the ceremony. The plant will consist of manufacturing facilities and auxiliary buildings with one basement level and three floors above ground, spanning 11,931 square meters on a 31,244-square-meter site.

Timeline to full operation

Construction is due to finish by late 2027, with building-use approval targeted for the end of that year. After regulatory procedures, including Good Manufacturing Practice certification, the company plans to gradually shift manufacturing from Namyangju and begin full-scale production at Hyangnam in 2029. HLB Pharmaceutical said the investment is intended to bring more production in-house, cut reliance on outside contract manufacturers and improve cost advantages.

The added capacity is also expected to back new product launches and the growth of its contract manufacturing organization, or CMO, business. The company described the site as a key manufacturing hub for HLB Group's pharmaceutical operations, supporting production of new drugs across the group, and said it is weighing further expansion of manufacturing infrastructure on adjacent land.

Record sales underpin the buildout

The move follows strong results. HLB Pharmaceutical posted USD 154.03 million in sales last year, crossing the USD 149.84 million threshold for the first time, and continued that momentum with a record USD 95.82 million in sales in the first half of this year, covering January to June.

Phased decade-long plan

The company's 10-year roadmap to 2036 unfolds in stages. From 2027 to 2028, the focus is on improving profitability. Between 2029 and 2031, HLB Pharmaceutical aims to strengthen its prescription drug portfolio through improved-drug development and expanded sales at general hospitals. After that, it plans to broaden its presence in oncology, urology and rare diseases while pursuing the introduction of blockbuster products and strategic mergers and acquisitions.

The overall strategy also includes strengthening the prescription drug business, developing improved versions of existing drugs and introducing new products. "Going beyond developing new cancer drugs, we will take a leap into becoming a company that stably supplies good drugs wanted by patients and medical staff to the world," Jin said.

Tracked in the database

Facility expansion · Asia-Pacific

Category

Facility expansion

Region

Asia-Pacific

Industry

Industrial

Published

12 November 2026

Length

3 min read

Tagged

HLB Pharmaceuticalpharmaceutical manufacturingtablet plant investmentcapacity expansion

Live from the tracker

The projects behind these stories

Capacity, capex, stage, contractors and verified contacts for every project we track, updated daily.

LLY - Lebanon Medicine Foundry · Indiana, United States · Not disclosed · On-going / Under Construction LLY - Project Savannah Biomanufacturing Facility · Texas, United States · Not disclosed · Planning LLY - Huntsville Medicines Manufacturing Plant · Alabama, United States · Not disclosed · Planning NOVO-B - Clayton Aseptic and Finished Product Manufacturing Plant · North Carolina, United States · Not disclosed · On-going / Under Construction LLY - Pleasant Prairie Pharmaceutical Manufacturing Facility Expansion · Wisconsin, United States · Not disclosed · Planning EDCL - Gopalganj Vaccine Manufacturing Plant · Dhaka Division, Bangladesh · Not disclosed · Planning FF - Holly Springs Cell Culture Biomanufacturing Plant · North Carolina, United States · Not disclosed · On-going / Under Construction LLY - Leiden Bio Science Park Pharmaceutical Manufacturing Plant · Netherlands · Not disclosed · Planning LLY - Alzey Pharmaceuticals Production Plant · Rhineland-Palatinate, Germany · Not disclosed · On-going / Under Construction BAYN - New Albany Pharmaceutical Manufacturing Plant · Ohio, United States · Not disclosed · Planning LLY - Lebanon Medicine Foundry · Indiana, United States · Not disclosed · On-going / Under Construction LLY - Project Savannah Biomanufacturing Facility · Texas, United States · Not disclosed · Planning LLY - Huntsville Medicines Manufacturing Plant · Alabama, United States · Not disclosed · Planning NOVO-B - Clayton Aseptic and Finished Product Manufacturing Plant · North Carolina, United States · Not disclosed · On-going / Under Construction LLY - Pleasant Prairie Pharmaceutical Manufacturing Facility Expansion · Wisconsin, United States · Not disclosed · Planning EDCL - Gopalganj Vaccine Manufacturing Plant · Dhaka Division, Bangladesh · Not disclosed · Planning FF - Holly Springs Cell Culture Biomanufacturing Plant · North Carolina, United States · Not disclosed · On-going / Under Construction LLY - Leiden Bio Science Park Pharmaceutical Manufacturing Plant · Netherlands · Not disclosed · Planning LLY - Alzey Pharmaceuticals Production Plant · Rhineland-Palatinate, Germany · Not disclosed · On-going / Under Construction BAYN - New Albany Pharmaceutical Manufacturing Plant · Ohio, United States · Not disclosed · Planning